Cognition Therapeutics publishes zervimesine study data

Cognition Therapeutics Inc. (NASDAQ: CGTX) published results from a proteomic analysis of its Phase 2 SEQUEL study examining zervimesine in adults with mild-to-moderate Alzheimer's disease. The manuscript appeared in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.

The SEQUEL study enrolled 16 adults with mild-to-moderate Alzheimer's disease, with 15 completing the crossover trial. Participants received either 300mg zervimesine or placebo daily for 29 days, followed by a 14-day washout period before switching treatments for another 29 days.

According to the published analysis, zervimesine treatment showed trends of improvement across prespecified EEG parameters. Slower brain wave frequencies called theta waves were reduced after 29 days of zervimesine treatment compared to placebo. The treatment was also associated with improvement in global alpha AEC-c, a measure of functional connectivity between brain regions.

Protein analysis revealed that zervimesine treatment altered proteins associated with vesicle formation, exocytosis and endosomal trafficking - cellular functions that allow neurons to recycle debris and transport necessary materials.

The company also conducted laboratory studies using neurons derived from human cell lines. When exposed to 4-hydroxynonenal (4-HNE), a molecule that induces oxidative stress found in high levels in neurodegenerative disease brains, more than 50% of cells died within 24 hours. However, when zervimesine was added with 4-HNE, cell viability was preserved.

"Our analysis from the SEQUEL study shows zervimesine has the ability to preserve the health and function of neurons that are under stress in Alzheimer's disease," said Mary Hamby, the company's VP of research.

The SEQUEL study was supported by $5.3 million in grant awards from the National Institute of Aging. Cognition Therapeutics is developing zervimesine as an oral, once-daily treatment for CNS diseases including Alzheimer's disease and dementia with Lewy bodies.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Mary Junck to retire from Lee Enterprises board in July
• Healthcare Triangle, Inc (HCTI) files for 28M share offering by selling stockholders